INVESTIGATION OF THE CONTENT OF EFFECTOR CELLS IN PERIPHERAL BLOOD OF PATIENTS WITH GLIOMAS OF DIFFERENT DEGREES OF MALIGNANCY
Keywords:
gliomas, degree of malignancy, peripheral blood, effector immune cells, lymphocytes, phenotype.Abstract
Summary. Aim: to investigate the changes in the subpopulation composition of peripheral blood lymphocytes
in patients with gliomas of varying degrees of malignancy before surgery. Object and Methods: samples the peripheral blood of neuronecological patients (41 samples)
and conditionally healthy persons (9 samples) were examined. Quantitative composition of subpopulations of
lymphocytes was studied on a flow cytofluorometer «FC500» («Beckman Coulter», USА) using dual monoclonal
antibody combinations («Beckman Coulter», USA). Statistical processing of the results was carried out with the
help of the Microsoft Excel program with the determination of the mean arithmetic and standard statistical deviation (m ± δ) and Student’s t-criterion. Results: contents of the main effector cells of the immune system —
cytotoxic lymphocytes (CTL), natural killer cells (NKCs)
ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ
ОНКОЛОГИЯ • Т. 20 • № 3 • 2018 217 217
and natural killer T cells (NSCTs) was found in peripheral blood of patients with brain tumors of different histogenesis. In patients with gliomas I–II degree of anaplasia, a slight decrease in the number of CTL, NSCLC
and NSC was determined in comparison with the corresponding indices of conditionally healthy persons. Malignant gliomas (III–IV degree of anaplasia) was accompanied by a statistically significant (p < 0.05) decrease
in the content of cells of these subpopulations compared
with those of not only conditionally healthy persons, but
also patients with gliomas of the I–II degree of anaplasia, as well as an increase in the content of lymphocytes,
expressing an apoptosis marker (CD95+). Conclusion: the
analysis of the subpopulation composition of peripheral
blood lymphocytes in patients with brain tumors suggests
References
Dix A, Brooks W, Roszman T, et al.Immune defects observed in patients with primary malignant brain tumours. J Neuroimmunol 1999; 100 (2): 216–32.
Parney I. Basic concepts in glioma immunology. In: Yamanaka R (ed). Glioma. Springer, New York, 2012: 42–52.
Lisyaniy NI. Changes in immune responses in various species of gliomas. In: Gliomas of the Brain. Zozylia UA (ed). K., UIPK «EksOb», 2007. 235–53 (in Ukrainian).
Avril T, Vauleon E, Hamlat A, et al. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol 2012; 22 (4): 159–74.
Friese M, Wischhusen J, Wick W, et al. RNA interference
targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. J Neurooncol 2014; 116 (1): 7121–3.
Alizadeh D, Zhang L, Brown C, et al. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res 2010; 16 (2): 3399–408.
Poli A, Wang J, Domingues O, et al. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget 2013; 4 (9): 1507–26.
Seidel U, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumour immunotherapy with therapeutic antibodies. Front Immunol 2013; 4: 76.
Hsia J, Chen J, Chen C, et al. Prognostic significance of intratumoural natural killer cells in primary resected esophageal squamous cell carcinoma. Chang Gung Med J 2005; 28 (5): 335–40.
Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88 (3): 577–83.
Kondo E, Koda K, Takiguchi N, et al. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg 2003; 20 (5): 445–51.
Ishikawa E, Tsuboi K, Saijo K, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004; 24 (3b): 1861–71.
Akinfieva OV, Bubnov LN, Bessmelshev SS. NKТ cells: characteristic features and functional significance in the immune response regulation. Onkogematologiya 2010; 4: 39–43 (in Russian).
Terabe M, Berzofsky JA, et al. The role of NKT cells in tumor immunity Adv Cancer Res 2009; 101: 277–348.
Kato S, Berzofsky J, Terabe M, et al. Possible therapeutic application of targeting type II natural killer T cell-mediated suppression of tumor immunity. Front Immunol 2018; 22 (9): 314.
Robertson F, Berzofsky J, Terabe M, et al. NKT cell networks in the regulation of tumor immunity. Front Immunol 2014; 5: 543.
Ambrosino E, Terabe M, Halder R. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 2007; 179 (8): 5126–36.
Hix L, Shi Y, Brutkiewicz R, et al. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One 2011; 6 (6): 20702.
Liao Y, Geng P, Tian Y, et al. Marked anti-tumor effects of CD8(+)CD62L(+) T-cells from melanoma-bearing mice. Immunol Invest 2015; 44 (2): 147–63.
Cagigi A, Nilsson A, Levitsky V, Sabri F. Cytotoxic T-lymphocytes secrete soluble factors that induce caspase-mediated
apoptosis in glioblastoma cell lines. J Neuroimmunol 2010; 225 (1–2): 34–42.
Kruse C, Cepeda L, Owens B, et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997; 45 (2): 77–87.
Xu L, Chen D, Lu C, et al. Advanced lung cancer is associated with decreased expression of perforin, CD95, CD38 by circulating CD3+CD8+ T lymphocytes. Ann Clin Lab Sci 2015; 45 (5): 528–32.
Tuncel T, Karagoz B, Haholu A, et al. Immunoregulatory function of HLA-G in gastric cancer. Asian Pacific J Cancer Prevent, 2013; 14 (12): 7681–4.
Parks DR, Herzenberg LA. Fluorescence-activated cell sorting: theory, experimental optimization, and applications in lymphoid cell biology. Methods Enzymol 1984; 108: 197–241.
Saggioro F, Neder L, Stávale J, et al.Fas, FasL, and cleaved caspases 8 and 3 in glioblastomas: a tissue microarray-based study. Pathol Res Pract 2014; 210 (5): 267–73.
Belskaya LN, Lisyany NI. Number CD4+CD25+ immunoregulatory cells at patients with glioma tumor. Immunol Allergol. Science Prakt 2011; 4: 50–3 (in Ukrainian).
Azuma T, Takahashi T, Kunisato A, et al. Human CD4+CD25+ regulatory T cells suppress NKT cell function. Cancer Res 2003; 63: 4516–20.
Freidlin IS. Regulatory T-cells: nature and functions. Med Immunol 2005; 7 (4): 347–54 (in Russian).
Lisyany NI, Belska LN. Immunosuppressive influence of the malignant brain tumors. Ukr Neurosurgical J 2007; (1): 4–9 (in Ukrainian).
